Literature DB >> 34035069

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Inna Smalley1, Zhihua Chen2, Manali Phadke3, Jiannong Li2, Xiaoqing Yu2, Clayton Wyatt3, Brittany Evernden4, Jane L Messina5,6, Amod Sarnaik5, Vernon K Sondak5, Chaomei Zhang7, Vincent Law4, Nam Tran4, Arnold Etame4, Robert J B Macaulay4,6, Zeynep Eroglu5, Peter A Forsyth4, Paulo C Rodriguez8, Y Ann Chen9, Keiran S M Smalley1,5.   

Abstract

PURPOSE: Melanoma brain metastases (MBM) and leptomeningeal melanoma metastases (LMM) are two different manifestations of melanoma CNS metastasis. Here, we used single-cell RNA sequencing (scRNA-seq) to define the immune landscape of MBM, LMM, and melanoma skin metastases. EXPERIMENTAL
DESIGN: scRNA-seq was undertaken on 43 patient specimens, including 8 skin metastases, 14 MBM, and 19 serial LMM specimens. Detailed cell type curation was performed, the immune landscapes were mapped, and key results were validated by IHC and flow cytometry. Association analyses were undertaken to identify immune cell subsets correlated with overall survival.
RESULTS: The LMM microenvironment was characterized by an immune-suppressed T-cell landscape distinct from that of brain and skin metastases. An LMM patient with long-term survival demonstrated an immune repertoire distinct from that of poor survivors and more similar to normal cerebrospinal fluid (CSF). Upon response to PD-1 therapy, this extreme responder showed increased levels of T cells and dendritic cells in their CSF, whereas poor survivors showed little improvement in their T-cell responses. In MBM patients, therapy led to increased immune infiltrate, with similar T-cell transcriptional diversity noted between skin metastases and MBM. A correlation analysis across the entire immune landscape identified the presence of a rare population of dendritic cells (DC3) that was associated with increased overall survival and positively regulated the immune environment through modulation of activated T cells and MHC expression.
CONCLUSIONS: Our study provides the first atlas of two distinct sites of melanoma CNS metastases and defines the immune cell landscape that underlies the biology of this devastating disease. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34035069      PMCID: PMC8282775          DOI: 10.1158/1078-0432.CCR-21-1694

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Single-Cell Signature Explorer for comprehensive visualization of single cell signatures across scRNA-seq datasets.

Authors:  Frédéric Pont; Marie Tosolini; Jean J Fournié
Journal:  Nucleic Acids Res       Date:  2019-12-02       Impact factor: 16.971

3.  Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?

Authors:  Silvia A Haueis; Pascale Kränzlin; Joanna Mangana; Phil F Cheng; Mirjana Urosevic-Maiwald; Ralph P Braun; Mitchell P Levesque; Reinhard Dummer; Simone M Goldinger
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

4.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

Review 5.  Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Authors:  Keiran S M Smalley; Inna V Fedorenko; Rajappa S Kenchappa; Solmaz Sahebjam; Peter A Forsyth
Journal:  Int J Cancer       Date:  2016-04-30       Impact factor: 7.396

Review 6.  Novel treatments for melanoma brain metastases.

Authors:  Rajappa S Kenchappa; Nam Tran; Nikhil G Rao; Keiran S Smalley; Geoffrey T Gibney; Vernon K Sondak; Peter A Forsyth
Journal:  Cancer Control       Date:  2013-10       Impact factor: 3.302

7.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma.

Authors:  Rita Cabrita; Martin Lauss; Adriana Sanna; Marco Donia; Mathilde Skaarup Larsen; Shamik Mitra; Iva Johansson; Bengt Phung; Katja Harbst; Johan Vallon-Christersson; Alison van Schoiack; Kristina Lövgren; Sarah Warren; Karin Jirström; Håkan Olsson; Kristian Pietras; Christian Ingvar; Karolin Isaksson; Dirk Schadendorf; Henrik Schmidt; Lars Bastholt; Ana Carneiro; Jennifer A Wargo; Inge Marie Svane; Göran Jönsson
Journal:  Nature       Date:  2020-01-15       Impact factor: 49.962

8.  Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.

Authors:  Alexandra-Chloé Villani; Rahul Satija; Gary Reynolds; Siranush Sarkizova; Karthik Shekhar; James Fletcher; Morgane Griesbeck; Andrew Butler; Shiwei Zheng; Suzan Lazo; Laura Jardine; David Dixon; Emily Stephenson; Emil Nilsson; Ida Grundberg; David McDonald; Andrew Filby; Weibo Li; Philip L De Jager; Orit Rozenblatt-Rosen; Andrew A Lane; Muzlifah Haniffa; Aviv Regev; Nir Hacohen
Journal:  Science       Date:  2017-04-21       Impact factor: 47.728

9.  Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Matteo S Carlino; Mary W F Azer; Peter J A Carr; Richard F Kefford; Georgina V Long
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

10.  B cells and tertiary lymphoid structures promote immunotherapy response.

Authors:  Beth A Helmink; Sangeetha M Reddy; Jianjun Gao; Shaojun Zhang; Rafet Basar; Rohit Thakur; Keren Yizhak; Moshe Sade-Feldman; Jorge Blando; Guangchun Han; Vancheswaran Gopalakrishnan; Yuanxin Xi; Hao Zhao; Rodabe N Amaria; Hussein A Tawbi; Alex P Cogdill; Wenbin Liu; Valerie S LeBleu; Fernanda G Kugeratski; Sapna Patel; Michael A Davies; Patrick Hwu; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Reetakshi Arora; Scott Woodman; Emily Z Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N Spencer; Elizabeth M Burton; Lauren E Haydu; Alexander J Lazar; Roberta Zapassodi; Courtney W Hudgens; Deborah A Ledesma; SuFey Ong; Michael Bailey; Sarah Warren; Disha Rao; Oscar Krijgsman; Elisa A Rozeman; Daniel Peeper; Christian U Blank; Ton N Schumacher; Lisa H Butterfield; Monika A Zelazowska; Kevin M McBride; Raghu Kalluri; James Allison; Florent Petitprez; Wolf Herman Fridman; Catherine Sautès-Fridman; Nir Hacohen; Katayoun Rezvani; Padmanee Sharma; Michael T Tetzlaff; Linghua Wang; Jennifer A Wargo
Journal:  Nature       Date:  2020-01-15       Impact factor: 69.504

View more
  11 in total

Review 1.  Leptomeningeal Metastases: New Opportunities in the Modern Era.

Authors:  Jessica A Wilcox; Min Jun Li; Adrienne A Boire
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 7.620

Review 2.  Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.

Authors:  Stergios J Moschos
Journal:  Am J Clin Dermatol       Date:  2022-05-09       Impact factor: 6.233

Review 3.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 4.  Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment.

Authors:  Kate Bridges; Kathryn Miller-Jensen
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

5.  Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.

Authors:  Jiannong Li; Inna Smalley; Zhihua Chen; Jheng-Yu Wu; Manali S Phadke; Jamie K Teer; Thanh Nguyen; Florian A Karreth; John M Koomen; Amod A Sarnaik; Jonathan S Zager; Nikhil I Khushalani; Ahmad A Tarhini; Vernon K Sondak; Paulo C Rodriguez; Jane L Messina; Y Ann Chen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

6.  Brain Microenvironment Heterogeneity: Potential Value for Brain Tumors.

Authors:  Laura Álvaro-Espinosa; Ana de Pablos-Aragoneses; Manuel Valiente; Neibla Priego
Journal:  Front Oncol       Date:  2021-09-01       Impact factor: 6.244

Review 7.  High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy.

Authors:  Camelia Quek; Xinyu Bai; Georgina V Long; Richard A Scolyer; James S Wilmott
Journal:  Genes (Basel)       Date:  2021-10-16       Impact factor: 4.096

Review 8.  Single-Cell RNA Sequencing of Cerebrospinal Fluid as an Advanced Form of Liquid Biopsy for Neurological Disorders.

Authors:  Anudeep Yekula; Jovanna Tracz; Jordina Rincon-Torroella; Tej Azad; Chetan Bettegowda
Journal:  Brain Sci       Date:  2022-06-22

Review 9.  High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses.

Authors:  Michael Heming; Anna-Lena Börsch; Heinz Wiendl; Gerd Meyer Zu Hörste
Journal:  Genome Med       Date:  2022-08-17       Impact factor: 15.266

10.  Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface.

Authors:  Miranda V Hunter; Reuben Moncada; Joshua M Weiss; Itai Yanai; Richard M White
Journal:  Nat Commun       Date:  2021-11-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.